We are pleased to announce that a Myristoylation Inhibition Sensitivity Signature of 91 genes (MISS-91) to identify patients who might benefit most from NMT inhibition therapy will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. New data demonstrating that PCLX-001, a proprietary, potent, N-myristoyltransferase (NMT) inhibitor reduces angiogenesis, cell migration/invasion, and thus potentially cancer metastasis, will also be presented.
“The promise of the gene signature research is personalized medicine,” said Luc Berthiaume, CSO of Pacylex. “Complementing this discovery, evidence continues to mount defining multiple ways that inhibiting myristoylation can affect cancers.”
In addition to presentation in the Poster Sessions at the AACR Annual Meeting 2023 in Orlando, Florida, the abstracts will be published in the online Proceedings of the AACR.